explore -WSS

explore

author：comprehensive 2025-10-03 00:38:42 - browse：825

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Free Covid tests will again be offered to all U.S. households

WSS

Humana sues Biden admin over Medicare Advantage audit rule

NIH nominee Bertagnolli will get October confirmation hearing

Humana sues Biden admin over Medicare Advantage audit rule

Midwives could help bridge maternal health disparities in the U.S.

NIH nominee Bertagnolli will get October confirmation hearing

Akili changes sales model for its ADHD video game treatment

leisure time

explore

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

A rare thyroid diagnosis led to unexpected, all

DIEP, the 'gold standard' of breast reconstruction, is under threat

Neurocrine congenital adrenal hyperplasia trial succeeds

23andMe had bad news about my health. I wish a person had delivered it

How generative AI is inspiring dreams of a health data revolution

Dobbs anniversary: the lost opportunity of abortion as health care

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Bright Health sells Medicare Advantage business to Molina

House transparency, PBM reform bill gains bipartisan support

focus

How generative AI is inspiring dreams of a health data revolution

Free Covid tests will again be offered to all U.S. households

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Ethical issues complicate the benefits of medical crowdfunding

People with substance use disorder deserve online privacy

Fed up with FDA, ALS advocates consider a take

hotspot

entertainment

hotspot

leisure time